Human adipose-derived stem cells (hASCs) offer great promise for bone tissue engineering because of their osteogenic differentiation potential. At molecular levels, this study investigated the contribution of one of the main members of mitogen-activated protein kinases (MAPKs), extracellular signal-related kinase (ERK), to hASC osteogenic differentiation and the regulation of ERK for the balance between osteogenesis and adipogenesis in hASCs in vitro. As analyzed using western blot, ERK activation in osteo-induced hASCs was initiated at day 7, peaked at day 10, and declined from day 14 to basal levels. As detected using histochemical and biochemical methods, alkaline phosphatase (ALP) activity in hASCs experienced a process similar to that of ERK activation. Inhibition of ERK activation by PD98059, a specific inhibitor of the ERK signaling pathway, blocked the osteogenic differentiation in a dose-dependent manner, as revealed by an ALP activity assay, extracellular calcium deposition detection, osteocalcin (OCN) secretion examination, and real-time polymerase chain reaction (PCR) analysis for expression of osteogenesis-relative genes: core binding factor alpha 1, collagen type I, ALP, and OCN. Blockage of ERK phosphorylation in osteo-induced hASCs by PD98059 supplemented with dexamethasone (Dex) led to adipogenic differentiation, as confirmed by Nile Red staining to detect intracellular lipid droplets and real-time PCR analysis for expression of adipogenesis-relative genes: peroxisome proliferator-activated receptor gamma 2 and fatty acid-binding protein. These findings indicated a potential mechanism for the function of ERK in hASC osteogenic differentiation, especially the regulation of ERK in association with Dex for the balance between osteogenesis and adipogenesis, pointing out the significance of ERK signaling pathway for ASCs as a promising cell source for bone tissue engineering.
Introduction
R ecent developments in bone tissue engineering has made it an attractive approach, with great potential for repairing bone defects, which remains a great challenge in orthopedic surgery. The basic strategy of tissue engineering involves the use of artificial biomaterials as scaffolds in combination with specific types of cells under the stimulation of growth factors to restore damaged bone structurally and functionally. 1 Seed cells, one of the most important issues in bone tissue engineering, play a pivotal role in extracellular matrix (ECM) deposition and homeostasis maintenance of regenerated tissues. Because of their promising osteogenic differentiation ability, bone marrow stromal cells (BMSCs) have been widely used as seed cells in bone tissue engineering, as documented in vitro and in vivo, [2] [3] [4] but because the obtainable amount of autologous bone marrow is limited, extensive in vitro culture is routinely required to achieve a therapeutic cell dose for the successful repair of a large bone defect using a tissue engineering approach. 5 As has been recognized, long-term in vitro culture is not good for cells to maintain their genomic stability. 6 Therefore, it is of great interest to find an alternative cell source that can overcome the inherent limitation of BMSCs without compromising osteogenic potential.
More recently, adipose-derived stem cells (ASCs) with multilineage potential have been identified in the stromal compartment of adipose tissue. 7, 8 ASCs are easier to obtain, 1 have relatively lower donor site morbidity and a higher yield at harvest, and can expand more rapidly in vitro than BMSCs. [9] [10] [11] Additionally, multipotency of ASCs was shown to be independent of serum source and quality. 9 Under appropriate conditions, 7, 12 ASCs can be induced into osteogenic lineage in vitro and therefore be anchored on proper scaffolds as seed cells to successfully repair bone defects in vivo. 10, 11 Thus, ASCs may be a novel and more promising alternative cell source for bone tissue engineering.
Although the osteogenic potential of ASCs has been characterized, 5, 7, 12 the underlying molecular mechanism responsible for their osteogenic lineage commitment remains to be revealed. It has been documented that activation of the mitogen-activated protein kinases (MAPKs) signaling pathway is involved in many fundamental proliferation and differentiation processes by regulating the response of cells to stimulation from hormones, cytokines, physical stress, and other environmental stimuli. [13] [14] [15] MAPKs are a widely conserved family of serine=threonine protein kinases of which the extracellular signal-related kinase (ERK) is a main member. 16 Proper soluble and insoluble cues can both activate ERK, whereas the activation of ERK through initiation of a sequential protein kinase cascade controls important cellular functions, especially differentiation programs of transcriptional and phenotypic modification. Involvement of the ERK pathway in osteogenic precursor commitment and osteoblast differentiation has been well established. It has been reported that the ERK signaling pathway regulates the commitment step of human BMSC (hBMSC) osteogenesis on bone marrow ECM proteins. 17 Zheng et al. 18 found that low phosphorylation of ERK induced by microgravity treatment reduced osteogenic differentiation of hBMSCs. In addition, Jaiswal et al. 19 documented that, under the treatment of traditional osteogenic induction system, the ERK pathway is one of the essential signaling pathways that control hBMSCs osteogenic differentiation in vitro. However, all of these reports were based on the traditionally used seed cells for bone tissue engineering. Because ASCs appear to be more promising for such purposes, it is of great interest to determine whether the ERK pathway plays a similar role in ASC osteogenic differentiation.
In addition to involvement in the osteogenesis process, the ERK pathway has also been found to be an important signaling mechanism in regulating adipogenic differentiation, although the results until now have been controversial. Prolonged inhibition of ERK expression using antisense oligonucleotides resulted in blockage of the differentiation of preadipocyte cell line 3T3 L1 into mature adipocytes. 20 Moreover, activation of the ERK pathway was found to be a prerequisite in the early stage of embryonic stem cell commitment into the adipocyte lineage induced by retinoic acid. 21 Furthermore, adipogenic differentiation of hBMSCs was initiated with attenuation of osteogenic differentiation resulting from the blockage of the ERK pathway. 19 It is well accepted that there exists a reciprocal balance between osteogenic and adipogenic differentiation of BMSCs, and disturbance of such balance was associated with osteoporosis, characterized by an increase of adipocytes in bone marrow. Based upon these findings, it could be speculated that ERK acts as a regulatory switch for the reciprocal regulation of osteogenesis and adipogenesis in BMSCs, although no report is available on whether or how ERK controls the balance between osteogenesis and adipogenesis in ASCs, another counterpart of BMSCs with mesenchymal origin. In addition, dexamethasone (Dex), usually presented in osteogenic medium (OM), was believed to be a crucial regulator for BMSC osteogenic differentiation, 22, 23 whereas recent studies have reported that osteogenic differentiation of ASCs was attenuated with the presence of Dex in the culture medium. 8, 24 Zuk et al. suggested that glucocorticoids, such as Dex, were not suitable for the osteogenic induction system for ASCs. 8 Zhou et al. reported that, unlike 1,25-dihydroxyvitamin D3, Dex suppressed osteogenic differentiation of ASCs, as revealed by extracellular calcium deposition and osteogenesis-relative gene expression. In addition, bone morphogenetic protein (BMP)-2 was expressed in 1,25-dihydroxyvitamin D3-osteo-induced differentiated ASCs but not in the Dex-treated group. 24 Hence, further work should be performed to identify the role of Dex in lineage commitment of multipotent ASCs.
In the present study, we sought to elucidate the role of the ERK pathway in regulating the osteogenic differentiation of human ASCs (hASCs). We also tried to block the ERK pathway using PD98059 to observe the adipogenic transition of hASCs in the presence or absence of Dex.
Materials and Methods
Harvest, culture, and differentiation of hASCs Fresh human lipoaspirates were obtained from five healthy female patients (average age 30) who had undergone abdominal liposuction at the Department of Plastic and Reconstructive Surgery of Shanghai 9th People's Hospital. The Research Ethical Committee of the hospital approved all procedures and protocols of human tissue handling. Processed lipoaspirate (PLA) cell isolation and culture were performed as previously described. 25 In brief, lipoaspirates were washed intensively with an equal volume of 0.1M phosphate buffered saline (PBS, pH 7.4) and digested with 0.075% collagenase type I (Washington Biochemical Corp., Lakewood, NJ) at 378C for 60 min. Enzyme activity was neutralized using low-glucose Dulbecco's modified Eagle medium (LG-DMEM, Gibco, New York) containing 10% fetal bovine serum (FBS, HyClone, Logan, UT), and the digested lipoaspirates were centrifuged at 1200 g for 10 min to obtain a high-density stromal vascular fraction (SVF). Then the SVF collection was treated with red blood cell lysing buffer (Sigma, St. Louis, MO) for 5 min, centrifuged at 600 g for 10 min, and filtered through a 100-mm nylon mesh to remove undigested tissue. Cells were resuspended in growth medium (GM) composed of LG-DMEM, 10% FBS, 100 mg=mL streptomycin, and 100 U=mL penicillin and plated at 4Â10 4 cells=cm 2 in F 100-mm culture dishes (Falcon, Oxnard, CA), with the medium changed twice a week. When 70% to 80% confluence was reached, cells were passaged, and those at passage 3 were used in the following study. The characterization of hASCs was determined according to their CD marker profile and their ability to differentiate into osteogenic, adipogenic, and chondrogenic lineages, as previously reported (data not shown). 8 For osteogenic differentiation, hASCs were cultured in osteogenic medium (OM) composed of the GM supplemented with 0.01 mM 1,25-dihydroxyvitamin D3, 50 mM ascorbate-2-phosphate, and 10 mM b-glycerophosphate. For adipogenic differentiation, cells were cultured in adipogenic medium (AM), which contained the GM supplemented with 0.5 mM isobutyl-methylxanthine (IBMX), 1 mM Dex, 10 mM insulin, and 200 mM indomethacin.
In experiments using the MAPK kinase 1 (MEK1) inhibitor PD98059 (Cell Signaling Technology, Beverly, MA), the 50mM stock solution was prepared in dimethyl sulfoxide (Me 2 SO) (Sigma) and then diluted to predetermined concentrations using the corresponding culture medium. The final concentration of Me 2 SO never exceeded 0.1% (v=v), and the same amount of Me 2 SO vehicle was added to control wells.
Alkaline phosphatase staining and activity assay
The hASCs at passage 3 were plated to 6-well plates (Falcon) and cultured in GM or OM. At days 4, 10, 14, and 17 after seeding, cultures were fixed using 4% paraformaldehyde for 2 min, rinsed two times using 20 mM Trishydrochloric acid (HCl), 0.15M sodium chloride (NaCl), 0.05% Tween-20 (TBST, pH 7.4) and then incubated in the nitro blue tetrazolium=5-bromo-4-chloro-3-indolyl phosphate (NBT=BCIP) ready-to-use solution (BM Purple ALP substrate precipitating, Roche, Mannheim, Germany) in the dark at room temperature for 20 min, according to the manufacturer's instructions. Cultures were photographed using a Nikon D60 digital camera (Nikon, Shanghai, P.R. China).
For ALP activity assay, cells were rinsed with cold PBS, scraped into 1.5-mL Eppendorf tubes in 1 mL of lysis buffer (10 mM Tris-HCl, 1 mM magnesium chloride, and 0.05% Triton X-100, pH 7.5), and then homogenized by sonication on ice. Afterwards, the resulting mixture was centrifuged at 12000 rpm for 10 min at 48C. The cell lysates (0.1 mL of the above supernatant) were mixed with 0.5 mL of p-nitrophenol (PNP) phosphate substrate solution (Sigma) and 0.5 mL of alkaline buffer solution (Sigma). After incubated at 378C for 15 min, the above mixture was added to 1 mL of 0.5N sodium hydroxide to stop the reaction and the absorbance at 405 nm was measured spectrophotometrically. A standard curve of known concentrations of PNP (Sigma) was generated concurrently and used to determine sample concentrations. The ALP activity (nmol of converted PNP=min) was normalized to the total protein content determined using the Pierce bicinchoninic acid (BCA) protein assay kit (Pierce Biotechnology, Rockford, IL) and expressed as nmol of converted PNP=min per mg of total protein. Nonseeded wells cultured with the same medium at each time point were treated in the same way and served as blank values that were then subtracted from the results of corresponding samples.
Accumulated calcium assay
Accumulated calcium deposition was observed using Alizarin Red S staining according to D'Ippolito et al. 26 In brief, cultures were fixed with 70% ice-cold ethanol for 1 h and then incubated in 40mM Alizarin Red S (Sigma) at pH 4.2 for 20 min at room temperature with agitation in an orbital shaker (60 rpm). After two intensive rinses with deionized water, ECM mineral-bound staining was photographed under a Nikon TE300 phase-contrast microscope (Nikon).
Accumulated calcium was extracted using 0.5 mL of 0.5N HCl and quantified according to the manufacturer's instructions in QuantiChrom Calcium Assay Kit (BioAssay Systems, Hayward, CA). Total calcium was calculated from standard solutions prepared in parallel and normalized to the total protein content. The values of blank controls were subtracted from the corresponding samples.
Osteocalcin secretion assay
Osteocalcin (OCN) content released in culture medium was also measured as previously described. 25 The samples were measured using a human Osteocalcin ELISA Kit (BioSource International Inc., Camarillo, CA) following the manufacturer's protocol. OCN concentration in the culture medium was quantified by correlation with a standard curve and further normalized to the total protein content. The values of blank controls were subtracted from the corresponding samples.
Nile Red staining
Adipogenic differentiation was assayed using Nile Red staining to detect the presence of intracellular lipid-filled droplets. Briefly, cells were fixed in 10% neutral buffered formalin for 30 min, washed with PBS, and stained with 1 mg=mL Nile Red (Sigma) in PBS for 20 min at room temperature. Nuclei of cells were counter-stained with 5 mg=mL Hoechst 33258 (Sigma). After two intensive rinses with deionized water, micrographs were taken using a fluorescence microscope (Nikon Y-FL).
Western blot analysis
Cultures were washed three times at predetermined time points with ice-cold PBS, and then the whole-cell extracts were obtained by lysing cells in cell lysis buffer (50 mM TrisHCl, 150 mM NaCl, 0.2 g=L sodium azide, 1 g=L sodium dodecyl sulfate (SDS), 0.1 g=L aprotinin, 10 g=L NP-40, 5 g=L sodium deoxycholate, 0.1 g=L phenylmethylsulphonyl fluoride, pH 8.0) on ice for 20 min. After being centrifuged at 12,000 rpm for 10 min at 48C, aliquots of the supernatants from the centrifuged cell lysates containing 20 mg of protein (determined using the Pierce BCA protein assay kit) were subjected to protein gel electrophoresis using 10% SDS polyacrylamide gel electrophoresis and transferred onto a polyvinylidene difluoride (PVDF) membrane (Amersham Life Sciences, Arlington Heights, IL) treated using 20% methanol in Tris-glycine buffer. After being blocked with PBS containing 5% bovine serum albumin for 2 h at room temperature, the membranes were incubated with 1:1000 diluted primary monoclonal mouse anti-human ERK (Cell Signaling Technology), phosphorylated (p-)ERK (Cell Signaling Technology), and b-actin (Sigma) antibodies at 48C overnight and then with 1:2000 diluted IRDye800-conjugated goat anti-mouse secondary antibody (Rockland Immunochemicals Inc., Gilbertsville, PA) for 1 h at room temperature. Signals were detected using the Odyssey Infrared Imaging System (LI-COR Biosciences, Lincoln, NE).
Quantitative real-time PCR
Total RNA was extracted from cell layers using a Trizol (Invitrogen, Carlsbad, CA) reagent according to the singlestep acid-phenol guanidinium extraction method. The concentration of RNA was determined from the optical absorbance at 260 nm of the extract. Complementary DNA
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(cDNA) was synthesized using the PrimeScript 1st Strand cDNA Synthesis kit (TaKaRa Biotechnology, Dalian, P.R. China). Reactions were performed and monitored in a T3 thermocycler (Biometra, Goettingen, Germany). Real-time PCR was performed using a quantitative real-time amplification system (MxPro-Mx3000P, Stratagene, La Jolla, CA). SybrGreen PCR MasterMix (Applied Biosystems, Foster City, CA) was used in each reaction. Reactions were performed with 40 cycles as follows: 958C for 30 s, annealing temperature for 30 s, and 728C for 45 s. Markers of osteogenic differentiation (core binding factor alpha 1 (Cbfa1), collagen type I (COL I), ALP, OCN) and markers of adipogenic differentiation (peroxisome proliferator-activated receptor gamma 2 (PPARg2) and fatty acid-binding protein (aP2)) were evaluated, and the bactin housekeeping gene served as the control (sequences of primers, individual annealing temperature, and amplicon lengths are shown in Table 1 ). Relative expression levels for each gene of interest were normalized to that of b-actin using the MxPro-Mx3000P system (Stratagene).
Statistical analysis
All experiments were performed in triplicate, and data are presented as means AE standard deviations. Statistical analyses for quantitative assays were performed using one-way analysis of variance assuming equal variance using SPSS 11.0 software (SPSS, Inc., Chicago, IL). A p-value less than 0.05 was considered statistically significant.
Results

Activation of ERK parallels to osteogenesis of hASCs
It was previously reported that, upon the onset of osteogenic differentiation of hASCs, osteogenic indicative markers were expressed in a time-dependent manner. 27 Thus, to observe the time course of osteogenic differentiation, levels of ALP activity in osteo-induced hASCs were determined at predetermined time points. As shown in Figure 1A , ALP staining in the OM group was in a scattered, weak fashion at day 4 and became more intense at days 10 and 14. The staining became weak again at day 17. At each time point tested, ALP staining in the GM group remained weak and sparse. A similar temporal profile of ALP expression was further documented using quantitative ALP activity assay (Fig. 1B) , which showed that ALP activity reached a peak level at approximately days 10 and 14 (both 2.3 times greater than the corresponding GM control groups), followed by a gradual decline (nearly 1.9 times greater than the GM control group at day 17) in the OM group. Thus, the results of this study showed that response of hASCs to OM stimulation was also time-dependent.
To investigate whether osteogenic differentiation of hASCs was parallel to the activation of ERK, we examined ERK activity at days 1, 4, 7, 10, 14, 17, and 21. As shown in Figure 2 , osteogenic differentiation of hASCs did not initiate ERK phosphorylation until 7 days of induction, although a robust, high level of ERK activity was observed at day 10, sustained until day 14, and followed by a decline to basal levels after 17 days of treatment. The time window when phosphorylation of ERK remained at a high level was associated with the maximal expression of ALP. Meanwhile, almost no detectable activation of ERK could be measured in the hASCs treated with GM at each time point checked. Taken together, these results indicated that the time-dependent pattern in osteogenic differentiation of hASCs correlated well with that in activation of ERK.
Blockage of ERK signaling pathway attenuates osteogenic differentiation of hASCs in a dose-dependent manner
To clarify whether ERK activation is necessary for osteogenic differentiation of hASCs, we blocked the ERK signaling pathway at different levels using PD98059, a potent and selective inhibitor of MEK1 (a kinase upstream of ERK), 28 with gradient concentrations in the presence of OM stimulation. Osteogenic differentiation of hASCs was determined according to ALP expression using the specific staining and quantitative assay. As shown in Figure 3A , treatment of hASCs with different concentrations of PD98059 (10, 25, and 50 mM) in OM resulted in concentration-dependent inhibition of ALP activity. Furthermore, as shown in Figure 3B , ALP levels were observed to be suppressed by 44.8%, 59.5%, and 83.5% with administration of PD98059 at concentrations of 10, 25, and 50 mM, respectively. However, ALP activity in each PD98059-treated OM group was still significantly higher than that in Table 1 the corresponding GM control groups in the presence of the same concentrations of PD98059 ( p < 0.05).
To confirm whether suppression of MEK1 activity caused inhibition of ALP activity by PD98059, we detected levels of ERK and p-ERK in the presence of PD98059 at concentrations of 10, 25, and 50 mM. According to Western blot analysis, a decrease in phosphorylation of ERK was parallel to the down-regulation of ALP activities inhibited by PD98059 in a similar dose-dependent manner (Fig. 4) .
Whether blockage of ERK signaling pathway with administration of PD98059 in gradient concentrations would affect extracellular deposition of calcium and OCN secretion of hASCs as well was then tested. As shown according to Alizarin Red S staining (Fig. 5A) , after 14 days of culture, osteo-induced cells growing in OM without addition of PD98059 showed intense positive staining for extracellular calcium deposition. With the increase in concentration of PD98059 added to OM, the staining became weaker and weaker. According to quantitative calcium deposition assay (Fig. 5B) , it was found that a 50 mM dose of PD98059 inhibited calcium deposition by 84.5%, whereas 25 and 10 mM PD98059 produced 53.0% and 33.8% inhibition, respectively. Furthermore, dose-dependent suppression of OCN secretion with administration of PD98059 was also detected as measured using the sensitive colorimetric assay (Fig. 5C ). OCN secretion in the group of OM containing 50 mM PD98059 decreased to a level without significant difference from that in the GM control group in the absence of PD98059 ( p > 0.05).
In addition, the effect of PD98059 on gene expression of Cbfa1, COL I, ALP, and OCN, which were well accepted as marker genes for osteogenic differentiation, was examined using real-time PCR. As shown in Figure 6 , osteo-induction of hASCs resulted in significantly greater expression of Cbfa1, COL I, ALP, and OCN than in hASCs cultured with GM. However, expression of all four of these genes was downregulated in a dose-dependent manner when gradient concentrations of PD98059 were introduced. Suppression of osteogenesis-related genes expression by blockage of the ERK pathway occurred not only in OM-treated hASCs, but also in cells cultured with GM. In the GM group, the expression of Cbfa1 and COL I in cells treated using 50 mM PD98059 was 67.5% and 83.4% less, respectivelythan in untreated cells. Thus, these results demonstrate that ALP activity and ECM mineralization at the protein and gene levels are associated directly with ERK activation and therefore that ERK plays a crucial role in osteogenic differentiation of hASCs.
Inhibition of the ERK pathway in osteogenesis leads to adipogenic differentiation of hASCs merely in the presence of Dex
As previously reported, activation or blockage of the ERK pathway regulated commitment of osteogenic or adipogenic differentiation of BMSCs. 19 We therefore investigated whether inhibition of ERK activation also contributed to adipogenesis of hASCs. Unexpectedly, hASCs cultured with GM or OM in the presence or absence of PD98059 treatment did not show any adipogenesis as detected using Nile Red staining (Fig. 7) . Because a major difference in culture supplements for ASC osteogenesis between our study and previous works was
FIG. 1.
Osteogenic induction increases alkaline phosphatase (ALP) activity in human adipose-derived stem cells (hASCs) at proper time points. Cells were cultured with growth medium (GM) or osteogenic medium (OM) in parallel. At the predetermined time points, cultures were stained using BM Purple to qualitatively detect ALP (A). Meanwhile, ALP activity was also quantified using the p-nitrophenol (PNP) phosphate-conversion method (B). *p < 0.05 vs respective GM controls, **p < 0.01 vs respective GM controls, ## p < 0.01 vs 1-day group cultured with OM. Color images available online at www.liebertonline.com=ten.
FIG. 2.
Osteogenic medium induces activation of extracellular signalrelated kinase (ERK) in hASCs. Cells were cultured with GM or OM in parallel; cell lysates at the indicated time points were subjected to immunoblot analysis using phospho-ERK-specific and non-activated ERK antibodies, with individual housekeeping b-actin served as control.
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the lack of Dex, which was routinely added for osteogenic differentiation of BMSCs, 8, 24 we supplemented with an additional 1Â10
À7
M Dex (a dose usually used for osteo-induction of BMSCs) to the GM and OM groups to see whether addition of Dex could induce osteo-differentiated or undifferentiated hASCs to undergo an adipogenic transition. Again, only a sporadic distribution of single adipocytes (stained as yellow-green fluorescence) could be observed in each treated group, although when Dex was added to cultures treated with 50 mM PD98059, intensive mature adipocytes could be observed in the OM group but not in the GM group. Consistent with these findings, results from real-time PCR analysis revealed that, with treatment with 1Â10 À7 M Dex, expression of PPARg2 (Fig. 8A) and aP2 (Fig. 8B) , two major adipogenesisrelated markers, was significantly up-regulated in PD98959-treated OM-induced hASCs, reaching 69.5% and 66.2%, respectively, of that in AM-induced hASCs. Taken together, these results demonstrate that adipogenic differentiation of hASCs promoted by Dex merely occurred in the circumstance that ERK-stimulated osteogenesis was attenuated.
Discussion
Although the osteogenic differentiation potential of ASCs in vitro and in vivo have been well documented in a variety of studies, 5, 7, 11 the molecular mechanism underlying their osteogenic commitment remains unclear. Elucidation of it could help to manipulate ASCs more efficiently toward osteogenic lineage in cell therapy and tissue-engineering strategy. As one of the major components of the MAPK family, ERK has been associated with cellular survival, proliferation, and differentiation 29 and especially the osteoblastic differentiation of BMSCs. 30, 31 Thus, one objective of this study was to investigate whether activation of the ERK pathway is involved in the differentiation of hASCs into osteogenic lineage. On the other hand, because of its well-defined regulatory effect on cellular growth and differentiation, Dex present in OM was usually deemed to contribute to the mitogenesis and osteogenic differentiation of BMSCs, which was reported to be in association with activation of the ERK pathway. 19 However, this is not the case for Dex in the regulation of ASC osteogenic differentiation. In the presence of Dex, osteogenesis of ASCs was found to be attenuated, as recent studies have reported. 8, 24 Therefore, the other goal of the current study was to investigate the effect of Dex on the differentiation process of hASCs and the role of the ERK pathway in such a process in the presence of Dex.
In this study, we found that, with treatment with OM, ERK was activated in a time-dependent manner that was consistent with the expression of ALP in hASCs. As one of the important markers of osteogenesis assessment, ALP was shown to regulate organic or inorganic phosphate metabolism via the hydrolyzation of phosphate esters and functioned as a plasma membrane transporter for inorganic phosphates. Hence, it can be concluded that ERK activation parallels the osteogenic differentiation of hASCs in vitro. To further investigate the role of the ERK pathway in hASC osteogenic differentiation, activation of the ERK pathway was blocked with the introduction of PD98059 in OM, and the corresponding osteogenic differentiation of hASCs was examined. PD98059 is a specific inhibitor of MEK1, a kinase upstream of ERK. It has been shown that PD98059 is able to bind to the FIG. 3. PD98059 inhibits ALP activity of hASCs in a dosedependent manner. Cells were cultured with GM or OM containing gradient concentrations (0, 10, 25, 50 mM) of PD98059 in parallel. At day 10, cultures were stained with BM Purple to qualitatively detect ALP (A). Meanwhile, ALP activity was also quantified using the PNP phosphateconversion method (B). The value of the OM group without PD98059 was set as 100%; the values of the other groups were expressed as a percentage of the OM group without PD98059. *p < 0.05 vs respective GM controls, **p < 0.01 vs respective GM controls, ## p < 0.01 vs 0 mM-dose group cultured with OM. Color images available online at www .liebertonline.com=ten.
FIG. 4.
PD98059 inhibits ERK activation in a dose-dependent manner. Cells were cultured with GM or OM containing gradient concentrations (0, 10, 25, 50 mM) of PD98059 in parallel. At day 10, cell lysates were analyzed according to immunoblot using phospho-ERK-specific and non-activated ERK antibodies; the individual housekeeping b-actin was also detected as control.
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inactive forms of MEK1 and block the ERK signaling pathway. 32 With the addition of PD98059 in a dose-dependent manner, expression of ALP was observed to be gradually inhibited, and when the concentration of PD98059 reached 50 mM in OM, expression of ALP was almost completely inhibited. To further address the role of ERK pathway blockage in osteogenic differentiation of hASCs, deposition of OCN and calcium by hASCs was quantified in the presence of PD98059. Osteocalcin is an established indicator of osteogenic differentiation and synthesized only by mature osteoblasts to bind collagen and calcium in the ECM of bone tissue. Calcium deposition is a characteristic of osteogenesis maturation and thus is deemed to be a distinguished marker for late differentiation of osteoblasts. In the current study, we found that deposition of OCN and calcium was suppressed in a similar way as that of ALP expression. Moreover, messenger RNA expression of COL I, ALP, and OCN was also inhibited with the interruption of the ERK pathway by PD98059. Thus, these results demonstrated that interruption of the ERK pathway leads to the blockage of the osteogenic differentiation of hASCs and further suggested that activation of the ERK pathway is especially responsible for osteogenesis of hASCs.
Of more importance, it was observed in this study that expression of Cbfa1, which is a key transcriptional activator of osteoblast differentiation, was remarkably suppressed with attenuation of ERK activation by PD98059. As has been reported, the activated ERK could physically interact with Cbfa1 and phosphorylate this transcription factor in vitro.
18
The function of Cbfa1 is dominant during osteoblast differentiation, which is characterized by its regulation of the expression of major osteogenesis-related genes, including COL I, ALP, and OCN, and by its role in maintaining the functions of differentiated osteoblasts at an early stage. 17 In particular, OCN is basically deemed to be a key downstream target of Cbfa1, and an increase in matrix mineralization usually follows the expression of OCN. 33 Several studies have documented the ERK?Cbfa1?OCN pathway in mature osteoblasts. 34, 35 Thus, the present study showed that the ERK? Cbfa1?osteogenic gene pathway might also work in hASCs during their osteogenic differentiation in vitro. It could be FIG. 5. Dose-dependent inhibition by PD98059 on calcium deposition and osteocalcin (OCN) secretion in hASCs. Cells were cultured with GM or OM containing gradient concentrations (0, 10, 25, 50 mM) of PD98059 in parallel. At day 14, cultures were stained with alizarin red to qualitatively detect calcium deposition (A). Bar scales: 100 mm. Extracellular calcium deposition was also quantified using colorimetric method (B). OCN content released by the cultures was also measured using a human osteocalcin enzyme-linked immunosorbent assay kit (C). ND, nondetectable; *p < 0.05 vs respective GM controls, **p < 0.01 vs respective GM controls, speculated that, with the treatment of OM in vitro, ERKdependent activation of Cbfa1 would lead to transcriptional cascades of the osteogenesis-related marker genes, which are finally followed by the mineralization of ECM. However, the exact effect of each component in OM, such as 1,25-dihydroxyvitamin D3, ascorbate-2-phosphate, and bglycerophosphate, in activation of the ERK pathway and thereby regulation of osteogenic differentiation of hASCs needs to be further explored. Jaiswal et al. have documented the existence of a reciprocal balance between osteogenesis and adipogenesis of hBMSCs under specific. 19 They found that interruption of the ERK signaling pathway by PD98059 would lead to the attenuation of osteogenic differentiation, thereby resulting in an automatic switch to adipogenic differentiation of hBMSCs. However, such phenotype conversion was not observed in this study according to the results of Nile Red staining when hASCs were osteo-induced and the ERK pathway was completely blocked in the presence of 50 mM PD98059. It was then speculated that the difference in components of OM between this study for ASC osteogenic induction and others for BMSC osteogenic induction might be responsible for this finding, because we supplemented the medium for osteogenic induction of hASCs with 1,25-dihydroxyvitamin D3 instead of Dex because several studies had questioned the efficacy of Dex in stimulating osteogenesis of ASCs, 8, 24 although Dex was usually added as an osteogenic stimulator for BMSCs. Thereafter, to further address the influence of Dex in osteogenic differentiation of ASCs, Dex was added in the GM and OM. It was found that hASCs cultured in Dex-supplemented OM differentiated along an adipogenic lineage when the ERK pathway was specifically blocked by PD98059. With further analysis using real-time PCR, we found that enhancement in expression of PPARg2 and aP2 with administration of Dex in osteo-induced hASCs merely occurred under the circumstance that ERK pathway was blocked by PD98059. PPARg2 is an isoform of the nuclear receptor PPARg, which is involved in the transcriptional control of adipogenesis and regarded as an early to mid marker of adipogenesis. 36, 37 AP2 is the mid to late marker of adipogenesis and acts through binding longchain acids and other hydrophobic ligands, controlling fatty acid uptake, transport, and metabolism. Its expression during adipocyte differentiation is in part regulated through the actions of PPARg. 38 As has been reported, PPARg possesses a MAPK phosphorylation consensus sequence at the N terminus, and phosphorylation of PPARg decreases its transcriptional activities and thus contributes to the anti-adipogenic effects. 19 So it can be speculated that blockage of ERK activation interrupts the MAPK-dependent phosphorylation of PPARg, contributing to the switch from osteogenesis to adipogenesis in hASCs. Taken together, these results indicated that there also exists a balance between osteogenesis and adipogenesis in hASCs and validated that Dex acts as a stimulator to initiate the switch from osteogenesis to adipogenesis when the ERK pathway is blocked.
Generally, the role of Dex in regulating osteogenesis and adipogenesis is reported to be dose dependent. Dex in low concentrations (1Â10 À7 M) is usually used for osteo-induction, whereas higher concentrations of Dex (1 or 2.5Â10 À6 M) are commonly administrated for induction of adipogenesis. 38, 39 In this study, we found that, when ERK activation was blocked by PD98059, Dex at concentrations as low as 1Â 10
À7
M was sufficient to induce adipogenic differentiation of hASCs. This result indicated that the ERK pathway may also be involved in adipogenic differentiation of hASCs. However, inconsistent with the results of the current study, a previous study using preadipocyte cell line 3T3-L1 showed that a specific inhibitor of the ERK pathway also leads to inhibition of adipogenesis. 20 In addition, activation of the ERK signaling pathway has been shown to be required at an early stage of adipogenesis in embryonic stem cells. 21 Although results were controversial, it is clear that the ERK pathway is an important signaling mechanism in regulating adipogenic differentiation. Thus, as demonstrated by our study, Dex in a low concentration works synergistically with ERK pathway blockage to promote adipogenic differentiation of osteo-induced hASCs. More recently, Hayashi et al. 40 reported that Dex down-regulated Runx-2 (Cbfa1) expression through enhancing expression of antagonists of BMP and Wnt, which is another important signal pathway in regulating osteogenesis. In addition, Osyczka et al. 41 suggested that the PI3-K=AKT pathway might be implicated in BMP-stimulated osteogenesis. It is believed that the balance of molecular events responding to various extracellular 
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stimuli determines the process of cell type-specific differentiation of multipotent mesenchymal stem cells. Therefore, other signaling pathways than ERK, such as c-Jun N-terminal kinase and p38, as well as cross-talk between these pathways need to be further identified to explore the deepened mechanism responsible for osteogenic differentiation of hASCs. Clear elucidation of the underlying mechanism will help us improve hASC osteogenic induction efficacy.
Conclusion
In summary, the current study found that the ERK pathway plays an important role in committing osteogenic differentiation of hASCs in vitro. Activation of ERK is especially related to the sequential expression of osteogenesis-related genes in hASCs, which further leads to ECM mineralization in later stages. The presence of Dex in osteo-induced medium resulted in a switch from osteogenesis to adipogenesis of hASCs when the ERK pathway was blocked.
